Thyroid safety in patients treated with liraglutide
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
During the last years, various novel anti-diabetic drugs have considerably enriched the therapeutic armamentarium for subjects with Type 2 diabetes. In the meantime, much interest has recently been focused on the potential cardiovascular and oncological adverse effects of these new therapies. As to glucagon-like peptide 1 (GLP-1) analogs, medullary thyroid tumors were reported to be more common in rodent toxicology studies with liraglutide, although the relevance of this finding in humans has been questioned. Analyses of sequential changes in calcitonin levels in several thousands of subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin. Furthermore, no medullary thyroid cancer has been detected in humans taking liraglutide. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and deserve further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [17]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“Data from these studies substantiated the following sequence of events, after long-term GLP-1R agonist exposition in rodents: 1) GLP-1R agonists bind to and activate GLP-1R on C-cells; 2) GLP-1R activation on C-cells induces calcitonin (Ct) release; 3) continued Ct release is followed by increased Ct synthesis by the…”
BackgroundInfluential
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Son, J. W., & Kim, S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0258 · Cited by 134
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Self-citationA Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sellarés, J., & Soler, M. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655871 · Cited by 101
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Seo, Y. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20059 · Cited by 65
Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?
Gallo, M., Ruggeri, R. M., Muscogiuri, G., Pizza, G., Faggiano, A., & Colao, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.013 · Cited by 57
Self-citationVekić, J., Zeljković, A., Stefanović, A., Giglio, R. V., Ciaccio, M., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212409 · Cited by 56
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., Tullio, A. D., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., Geronimo, V. D., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 50
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Çaklılı, Ö. T., Cesur, M., Mikhailidis, D. P., & Rizzo, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392684 · Cited by 37
Fan, M., Jiang, H., Zhang, Y., Ma, Y., Li, L., & Wu, J. (2018) · Medical Science Monitor · doi:10.12659/msm.906286 · Cited by 32
Diabetology and oncology meet in a network model: union is strength
Gallo, M., Gentile, L., Arvat, E., Bertetto, O., & Clemente, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0839-z · Cited by 29
Self-citationThe role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18
Cao, Y., & Liu, X.-M. (2014) · Endocrine · doi:10.1007/s12020-014-0354-3 · Cited by 14
Peptide and protein based pharmaceuticals
Mező, G. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737081-00203 · Cited by 18
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 155
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
Medications Available for Weight Reduction in Elective Total Joint Arthroplasty
Amanatullah, D. F., Ohanisian, L. L., & Bailony, M. R. (2020) · JBJS Reviews · doi:10.2106/jbjs.rvw.19.00123 · Cited by 10
Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?
Gallo, M., Monami, M., Ragni, A., & Renzelli, V. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110624 · Cited by 7
Self-citationRecent Advances in Anti-Obesity Drugs
Son, J. W. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.113 · Cited by 5
Pollack, R. M., & Stokar, J. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70104 · Cited by 5
Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity
Akkurt, A. (2023) · Cureus · doi:10.7759/cureus.50544 · Cited by 1
The emerging role of GLP-1 analogs in weight control
Filho, S. S., Comby, I., Garcez, L. R., Moreira, T. A., Braga, T. D. O., Miranda, S. C. D., Silva, G. A. B. E., & Quartezani, T. E. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-426 · Cited by 1
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Ueda, P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70170
Metadata
- Authors
- Gallo, M.
- Affiliations
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Corresponding author
- Gallo, M.
- ORCID
- Gallo, M.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2013-02
- Volume
- 36
- Issue
- 2
- Pages
- 140-145
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2086006571
- Cited by
- 27
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 4 · 2020: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- liraglutide, medullary thyroid carcinoma, GLP-1 receptor agonists, type 2 diabetes, calcitonin, drug safety
- MeSH terms
- Liraglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Gland, Thyroid Neoplasms, Randomized Controlled Trials as Topic, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.